Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Synthetic lethality-mediated precision oncology via the tumor transcriptome

ABSTRACT: Synthetic lethality-mediated precision oncology via the tumor transcriptome

PROVIDER: PRJNA700986 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13667965_1.fastq.gz	Fastqsanger.gz
	SRR13667965_2.fastq.gz	Fastqsanger.gz
	SRR13667966_1.fastq.gz	Fastqsanger.gz
	SRR13667966_2.fastq.gz	Fastqsanger.gz
	SRR13667967_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 44

Similar Datasets

Synthetic lethality-mediated precision oncology via the tumor transcriptome

Project description:Precision oncology has made significant advances in the last few years, mainly by targeting actionable mutations in cancer driver genes. However, the proportion of patients whose tumors can be targeted therapeutically remains limited. Recent studies have begun to explore the benefit of analyzing tumor transcriptomics data to guide patient treatment, raising the need for new approaches for systematically accomplishing that. Here we show that computationally derived genetic interactions can successfully predict patient response.

2021-02-11 | GSE166449 | GEO

Synthetic lethality-mediated precision oncology via the tumor transcriptome.

Project description:Precision oncology has made significant advances, mainly by targeting actionable mutations in cancer driver genes. Aiming to expand treatment opportunities, recent studies have begun to explore the utility of tumor transcriptome to guide patient treatment. Here, we introduce SELECT (synthetic lethality and rescue-mediated precision oncology via the transcriptome), a precision oncology framework harnessing genetic interactions to predict patient response to cancer therapy from the tumor transcriptome. SELECT is tested on a broad collection of 35 published targeted and immunotherapy clinical trials from 10 different cancer types. It is predictive of patients' response in 80% of these clinical trials and in the recent multi-arm WINTHER trial. The predictive signatures and the code are made publicly available for academic use, laying a basis for future prospective clinical studies.

| S-EPMC9310669 | biostudies-literature

SML1 synthetic lethality

Project description:Assessment of synthetic lethality between an sml1 null mutation and Yeast Deletion mutations Keywords = SML1 Keywords = yeast Keywords = deletion Keywords = synthetic lethality Keywords = tag Keywords = barcode Keywords: repeat sample

2004-11-05 | GSE1765 | GEO

SGS1 synthetic lethality

Project description:Assessment of synthetic lethality between an sgs1 null mutation and Yeast Deletion mutations Keywords = SGS1 Keywords = yeast Keywords = deletion Keywords = synthetic lethality Keywords = tag Keywords = barcode Keywords: repeat sample

2004-11-05 | GSE1757 | GEO

BIM1 synthetic lethality

Project description:Assessment of synthetic lethality between a bim1 null mutation and Yeast Deletion mutations Keywords = BIM1 Keywords = yeast Keywords = deletion Keywords = synthetic lethality Keywords = tag Keywords = barcode Keywords: repeat sample

2004-11-05 | GSE1756 | GEO

CIN8 Synthetic Lethality

Project description:Assessment of synthetic lethality between a cin8 deletion mutation and Yeast Deletion mutations. Keywords = CIN8 Keywords = yeast Keywords = deletion Keywords = synthetic lethality Keywords = tag Keywords = barcode Keywords: repeat sample

2004-11-05 | GSE1754 | GEO

LCD1-overexpression synthetic lethality

Project description:Assessment of synthetic lethality between an overexpressed LCD1 gene and Yeast Deletion mutations Keywords = LCD1 Keywords = overexpression Keywords = yeast Keywords = deletion Keywords = synthetic lethality Keywords = tag Keywords = barcode Keywords: repeat sample

2004-11-05 | GSE1759 | GEO

CDC102 synthetic lethality

Project description:Assessment of synthetic lethality between a temperature-sensitive allele of CDC102 and Yeast Deletion mutations Keywords: repeat sample

2004-11-05 | GSE1758 | GEO

Patient-derived micro-organospheres (MOS) enable clinical precision oncology

Project description:Patient-derived xenografts (PDX) and organoids (PDO) have been shown to model clinical response to cancer therapy. However, it remains challenging to use these models to guide timely clinical decisions for cancer patients. Here we used droplet emulsion microfluidics with temperature control and dead-volume minimization to rapidly generate thousands of Micro- Organospheres (MOS) from low-volume patient tissues, which serve as an ideal patient-derived model for clinical precision oncology. A clinical study of newly diagnosed metastatic colorectal cancer (CRC) patients using a MOS-based precision oncology pipeline reliably predicted patient treatment outcome within 14 days, a timeline suitable for guiding treatment decisions in clinic. Furthermore, MOS capture original stromal cells and allow T cell penetration, providing a clinical assay for testing immuno-oncology (IO) therapies such as PD-1 blockade, bispecific antibodies, and T cell therapies on patient tumors.

2022-09-01 | GSE184242 | GEO

The OncoLoop Network-based Precision Oncology Framework

Project description:The OncoLoop Network-based Precision Oncology Framework

| PRJNA774549 | ENA